Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 持股5%以上股东减持计划时间届满暨减持结果公告 | 2024-03-01 | Chinese | |
| 百奥泰 2023年度业绩快报公告 | 2024-02-23 | Chinese | |
| 百奥泰 关于证券事务代表辞职的公告 | 2024-02-19 | Chinese | |
| 百奥泰 2023年年度业绩预亏公告 | 2024-01-29 | Chinese | |
| 百奥泰 自愿披露关于BAT7104注射液联合BAT4706注射液治疗晚期恶性肿瘤获得药物临床试验批准通知书的公告 | 2024-01-11 | Chinese | |
| 百奥泰 关于公司股东权益变动进展暨股份完成证券过户登记的公告 | 2023-12-22 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
5 filings
| |||||
| 39228027 | 百奥泰 持股5%以上股东减持计划时间届满暨减持结果公告 | 2024-03-01 | Chinese | ||
| 39228020 | 百奥泰 2023年度业绩快报公告 | 2024-02-23 | Chinese | ||
| 39228016 | 百奥泰 关于证券事务代表辞职的公告 | 2024-02-19 | Chinese | ||
| 39228009 | 百奥泰 2023年年度业绩预亏公告 | 2024-01-29 | Chinese | ||
| 39228003 | 百奥泰 自愿披露关于BAT7104注射液联合BAT4706注射液治疗晚期恶性肿瘤获得药物临床试验批准通知书的公告 | 2024-01-11 | Chinese | ||
|
2023
10 filings
| |||||
| 39227999 | 百奥泰 关于公司股东权益变动进展暨股份完成证券过户登记的公告 | 2023-12-22 | Chinese | ||
| 39227986 | 百奥泰 自愿披露关于BAT1308注射液联合含铂化疗治疗子宫内膜癌获得药物临床试验批准通知书的公告 | 2023-12-15 | Chinese | ||
| 39227969 | 百奥泰 关于BAT1706（贝伐珠单抗）注射液获得美国FDA上市批准的公告 | 2023-12-07 | Chinese | ||
| 39227959 | 百奥泰 2023年度向特定对象发行A股股票发行方案论证分析报告（修订稿） | 2023-12-01 | Chinese | ||
| 39227943 | 百奥泰 关于2023年度向特定对象发行A股股票预案修订说明的公告 | 2023-12-01 | Chinese | ||
| 39227937 | 百奥泰 监事会关于公司2023年度向特定对象发行A股股票相关事项的书面审核意见 | 2023-12-01 | Chinese | ||
| 39227922 | 百奥泰 第二届监事会第十二次会议决议的公告 | 2023-12-01 | Chinese | ||
| 39227914 | 百奥泰 独立董事关于第二届董事会第十三次会议相关事项的独立意见 | 2023-12-01 | Chinese | ||
| 39227872 | 百奥泰 简式权益变动报告书 | 2023-12-01 | Chinese | ||
| 39227859 | 百奥泰关于2023年度向特定对象发行A股股票预案（修订稿）披露的提示性公告 | 2023-12-01 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.